Effect of clopidogrel treatment on stress-induced platelet activation and myocardial ischemia in aspirin-treated patients with stable coronary artery disease

Summary

Stress may counteract responses to antiplatelet drug treatment. We investigated if adding clopidogrel to aspirin treatment could attenutate stress-induced platelet activation and myocardial ischemia in patients with coronary artery disease (CAD). Thirty-one male patients with documented CAD-treated with aspirin (75–160 mg daily) were randomized to co-treatment with clopidogrel (n=16) or placebo (n=15). A symptom-limited exercise test and 48-hour (h) Holter monitoring were performed before and after two weeks of double-blind treatment. Platelet function was assessed by flow cytometry and impedance aggregometry in whole blood. Exercise-induced and ambulatory ischemia was assessed from electrocardiographic (ECG) recordings. Clopidogrel treatment inhibited ADP-induced platelet P-selectin expression by 64% (22–87%), and attenuated the P-selectin response to thrombin (p<0.001), and platelet aggregation induced by low-dose collagen (p<0.01). Exercise (≈110W) increased heart rate similarly, and caused ≈1.8 mm STsegment depression both before and after treatment. Exercise caused platelet activation, i.e. increased circulating activated single platelets and platelet-platelet aggregates, enhanced the invitro responsiveness to ADP or thrombin stimulation, and increased platelet-leukocyte aggregation. Clopidogrel inhibited ADP-induced platelet activation to a similar relative degree at rest and during exercise, but did not attenuate the platelet activating effect of exercise. Addition of clopidogrel to aspirin treatment did not attenuate either ambulatory or exercise-induced ischemia. In conclusion, adding clopidogrel to aspirin treatment inhibited platelet activation by both ADP, thrombin and collagen in vitro,but did not influence the prothrombotic responses to exercise. Intensified antiplatelet treatment did not reduce ECG signs of either exercise-induced or ambulatory myocardial ischemia.

Keywords

Clopidogrel - aspirin - exercise - platelets - myocardial ischemia

• References

• 1 Wagner DD, Burger PC. Platelets in inflammation and thrombosis. Arterioscl Thromb Vasc Biol 2003; 23: 2131-2137.
• 2 Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115: 3378-3384.
• 3 da Costa Martins P, Zwaginga J-J. Leukocyte-platelet aggregates: new particles reflecting and effecting cardiovascular disease. Thromb Haemost 2005; 94: 1120-1121.
• 4 Antithrombotic Trialists´ Collaboration.. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
• 5 Savi P, Nurden P, Nurden AT. et al. Clopidogrel: a review of its mechanism of action. Platelets 1998; 9: 251-255.
• 6 Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost 2001; 86: 222-232.
• 7 Yusuf S, Zhao F, Mehta SR. et al. for The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New Engl J Med 2001; 345: 494-502.
• 8 Tofler GH, Muller JE. Triggering of acute cardiovascular disease and potential preventive strategies. Circulation 2006; 114: 1863-1872.
• 9 Kestin AS, Ellis PA, Barnard MR. et al. Effect of strenuous exercise on platelet activation state and reactivity. Circulation 1993; 88: 1502-1511.
• 10 Wallén NH, Held C, Rehnqvist N, Hjemdahl P. Effects of mental and physical stress on platelet function in patients with stable angina pectoris and healthy controls. Eur Heart J 1997; 18: 807-815.
• 11 Li N, Wallén NH, Hjemdahl P. Evidence for prothrombotic effects of exercise and limited protection by aspirin. Circulation 1999; 100: 1374-1379.
• 12 Kroll MH, Hellums JD, MacIntire LV. et al. Platelets and shear stress. Blood 1996; 88: 1525-1541.
• 13 Sakariassen KS, Hanson SR, Cadroy Y. Methods and models to evaluate shear-dependent and surface reactivity-dependent antithrombotic efficacy. Thromb Res 2001; 104: 149-174.
• 14 Ruggeri ZM. Old concepts and new developments in the study of platelet aggregation. J Clin Invest 2000; 105: 699-701.
• 15 Xiao Z, Théroux P. Clopidogrel inhibits plateletleukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. J Am Coll Cardiol 2004; 43: 1982-1989.
• 16 Perneby C, Wallén NH, Hu H. et al. Prothrombotic responses to exercise are little influenced by clopidogrel treatment. Thromb Res 2004; 114: 135-143.
• 17 Willerson JT, Golino P, Eidt J. et al. Specific platelet mediators and unstable coronary artery lesions: experimental evidence and potential clinical implications. Circulation 1989; 80: 198-205.
• 18 Fox K, Jonathan A, Selwyn AP. Effects of platelet inhibition on myocardial ischemia. Lancet 1982; ii: 727-730.
• 19 Mahoney C. Effects of aspirin on myocardial ischemia. Am J Cardiol 1989; 64: 387-389.
• 20 Ikonomidis I, Andreotti F. Nihoyannopoulos Reduction of daily life ischemia by aspirin in patients with angina: underlying link between thromboxane A2 and macrophage colony stimulating factor. Heart 2004; 90: 389-393.
• 21 Khurmi NS, Bowles MJ, Raftery EB. Are anti-platelet drugs of value in the management of patients with chronic stable angina? A study with ticlopidine. Clin Cardiol 1986; 9: 493-498.
• 22 Berglund U, Lasswik C, Wallentin L. Effects of the platelet inhibitor ticlopidine on exercise tolerance in stable angina pectoris. Eur Heart J 1987; 8: 25-30.
• 23 Li N, Goodall A, Hjemdahl P. An efficient flow cytometric assay for platelet-leukocyte aggregates in whole blood using fluorescence signal triggering. Cytometry 1999; 35: 154-161.
• 24 Li N, Halldén G, Hjemdahl P. A whole blood flow cytometric assay for leukocyte CD11b expression using fluorescence signal triggering. Eur J Haematol 2000; 65: 57-65.
• 25 Malms Tröm RE, Östergren J, Jørgensen L. et al. Influence of statin treatment on the ADP responsiveness of platelets during clopidogrel treatment – a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment. J Am Coll Cardiol 2007 49. (Suppl A): Abstract #804–5.
• 26 Michelson AD, Barnard MR, Kreuger LA. et al. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin. Circulation 2001; 104: 1533-1537.
• 27 Andreotti F, Lanza GA, Schiahbasi A. et al. Lowgrade exercise enhances platelet aggregability in patients with obstructive coronary artery disease independently of ischemia. Am J Cardiol 2001; 87: 16-20.
• 28 Siller-Matula J, Schrör K, Wojta J, Huber K. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thromb Haemost 2007; 97: 385-393.
• 29 O´Donoghue M, Wiviott SD. Clopidogrel response variability and future therapies – Clopidogrel: Does one size fit all?. Circulation 2006; 114: 600-606.
• 30 Pampuch A, Cerletti C, de Gaetano G. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptor. Thromb Haemost 2006; 96: 767-773.
• 31 Evangelista V, Manarini S, Dell’Elba G. et al. Clopidogrel inhibits platelet-leukocyte adhesion and platelet-dependent leukocyte activation. Thromb Haemost 2005; 94: 568-577.
• 32 Ikonomidis A, Andreotti F, Economou E. et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999; 100: 793-798.
• 33 André P, Nannizzi-Alaimo L, Prasad SK. et al. Platelet- derived CD40L – the switch-hitting player of cardiovascular disease. Circulation 2002; 106: 806-809.
• 34 Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nature Drug Discovery 2003; 2: 15-28.
• 35 Heitzer T, Rudolph V, Schwedhelm E. et al. Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease – evidence for antioxidant and antiinflammatory effects. Arterioscl Thromb Vasc Biol 2006; 26: 1648-1652.
• 36 Azar RR, Kassab R, Zoghbi A. et al. Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease. Am Heart J 2006; 151: 521.e1-521.e4.